ArticleBreast cancer (Tokyo, Japan)2026

UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer.

Ana Gil-Torralvo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.